IRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that bariatric surgical fellows from
COVID-19 survivors who have long-term memory problems are at higher risk for Alzheimer's dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.
◆
A former post-doctoral fellow at the McGovern Medical School, part of the University of Texas (UT) Health Science Center, admitted to committing research misconduct by “knowingly and intentionally falsifying, fabricating, and plagiarizing data and text” in six papers and eight manuscripts, according to the HHS Office of Research Integrity (ORI). In its Feb. 4
Federal Register notice, ORI said Yibin Lin “falsely created fictitious author names and affiliations without listing himself as an author to disguise himself from being the offender, and submitted them for publication in
bioRxiv and
medRxiv, open access preprint repositories, by falsely assembling random paragraphs of text, tables, and figures from previous publications and manuscripts to improve his citation metrics.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a .
BioXcel TherapeuticsFebruary 12, 2021 GMT
NEW HAVEN, Conn., Feb. 12, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the Company will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am ET to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”), and its potential as a treatment option for multiple neuropsychiatric conditions.